QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aeglea-biotherapeutics-announces-name-change-to-spyre-therapeutics-appoints-ceo-and-additional-directors-and-expands-leadership-team-to-develop-next-generation-therapeutic-combinations-for-the-treatment-of-ibd

Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023Biotechnology leader Camero...

 wuxi-biologics-obligated-to-pay-a-service-fee-and-all-non-cancellable-obligations-specified-in-each-work-order-with-termination-possible-upon-completion-of-services-or-with-prior-notice-for-certain-reasons

- SEC Filing

 paragon-therapeutics-inc-and-wuxi-biologics-entered-into-a-biologics-master-services-agreement-which-was-later-transferred-to-aeglea-biotherapeutics-inc-governing-development-activities-and-manufacturing-for-the-companys-spy001-program

- SEC Filing

 aeglea-biotherapeutics-announces-1-for-25-reverse-stock-split

 Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therap...

 wells-fargo-maintains-equal-weight-on-aeglea-biotherapeutics-raises-price-target-to-05

Wells Fargo analyst Yanan Zhu maintains Aeglea BioTherapeutics (NASDAQ:AGLE) with a Equal-Weight and raises the price target...

 aeglea-biotherapeutics-q2-eps-227-misses-015-estimate-sales-68800k-beat-20000k-estimate

Aeglea BioTherapeutics (NASDAQ:AGLE) reported quarterly losses of $(2.27) per share which missed the analyst consensus estimate...

 aeglea-biotherapeutics-has-agreed-to-sell-the-global-rights-to-pegzilarginase-an-investigational-treatment-for-the-rare-metabolic-disease-arginase-1-deficiency-to-immedica-pharma-for-15m-in-upfront-cash-and-up-to-100m-in-contingent-milestone-payments

The sale of pegzilarginase to Immedica supersedes the previous license agreement between Aeglea and Immedica.  

 stifel-initiates-coverage-on-aeglea-biotherapeutics-with-buy-rating-announces-price-target-of-09

Stifel analyst Alex Thompson initiates coverage on Aeglea BioTherapeutics (NASDAQ:AGLE) with a Buy rating and announces Pric...

 10-short-squeeze-stocks-to-watch-aeglea-biotherapeutics-toro-corp-airsculpt-a-company-moves-up-4166-positions--more

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for th...

 why-tivic-health-systems-are-trading-lower-by-23-here-are-20-stocks-moving-premarket

Gainers Nanobiotix S.A. (NASDAQ: NBTX) shares surged 59.3% to $8.02 in pre-market trading after the company entered into a l...

 why-gorilla-technology-group-are-trading-higher-by-52-here-are-20-stocks-moving-premarket

Gainers Gorilla Technology Group Inc. (NASDAQ: GRRR) shares surged 51.7% to $3.17 in pre-market trading after the company si...

 deep-track-capital-reports-a-999-stake-in-aeglea-biotherapeutics

-SEC Filing

 why-virgin-galactic-are-trading-lower-by-around-18-here-are-20-stocks-moving-premarket

Gainers Castellum, Inc. (NYSE: CTM) shares surged 176.6% to $1.25 in pre-market trading after dropping around 6% on Thursday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION